Dr. Kinoshita is evaluating the immunobiology of multi-antigen specific T-cell therapy infused to patients to reduce the two most common causes of morbidity and mortality following stem cell transplant—cancer relapse and infection.
Multi-antigen Specific T cells post-Hematopoietic Stem Cell Transplant to Enhance anti-Leukemia and anti-Viral Immunity in vivo
Momentum Fellow (2021-Present)
Hannah Kinoshita, MD, Children's National Hospital
Hannah Kinoshita, MD